DadFinStart your free week
DadFin › Stocks › Healthcare › ANIK

Anika Therapeutics, Inc. (ANIK) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$19.58 ▲ +1.82% today

37.8
Dad Score, out of 100
weak

Anika Therapeutics, Inc. (ANIK) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 37.8 out of 100 on the Dad Score, a weak reading that places the business ahead of 38% of the 5,773 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #533 of 968. Its strongest axes are quality and macro; its weakest are growth and liquidity.

Scores from the run of Oct 11, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Above average
Growth
Below average
Price action
Average
Risk
Average
Conviction
Average
Liquidity
Below average
Macro
Strong

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)20.6×
Dividend yield0.00%
Return on capital-6.1%
Operating margin11.4%
Revenue growth (YoY)-5.9%
FCF yield2.1%
Net debt / EBITDA-4.33×
Piotroski F-Score5 / 9
52-week change+115.2%
Market cap$262M
Next earnings—

What subscribers see on ANIK

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi50.0middling$59.8B
TEVATeva Pharmaceutical Industries Lim96.8strong$47.9B
HLNHaleon plc69.5middling$41.0B
ZTSZoetis Inc.94.4strong$30.9B
UTHRUnited Therapeutics Corporation99.1strong$23.6B
VTRSViatris Inc.84.5good$20.3B
NBIXNeurocrine Biosciences, Inc.98.7strong$14.5B
ELANElanco Animal Health Incorporated96.2strong$11.5B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 11, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.